Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Biotechnology

Healthcare
$305.19 +4.49%

+$12.13 today

Market cap
$8.53B
Beta
2.75
P/E (TTM)
-25.0
EPS (TTM)
-$11.31
52W Low $37.19High $366.52

Volume 0.43M

Average 0.45M

PRAX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Praxis Precision Medicines, Inc.NASDAQ: PRAX

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables turns negative

Q3 FY2026 accounts payables was -$8.26M, compared with $1.99M a year earlier. Trailing-twelve-month accounts payables was -$15.8M. Over 3 fiscal years it compounded at +45.9% a year.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near -$8.26M or moves back toward the trailing-twelve-month quarterly average of -$3.95M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$8.26M+4.8% QoQ
Last fiscal yearDec 2025
$12.1M+80.2% YoY
LTMSep 2026
-$15.8M-200.0% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-515.6%——
1 year+80.2%——
3-year CAGR+45.9%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
12.1M USD
Year-over-year change
+80.2%
4-year CAGR
+13.6%

Accounts Payables vs competitors

How PRAX compares with its peers on the latest reported figures

  • PRAX's LTM Sep 2026 accounts payables of $15.8M is the 4th largest of the 10 companies compared; the peer median is $3.67M.
  • Its year-over-year change of -200.0% is the 8th highest of 9, against a peer median of +150.0%.
  • Over three fiscal years its annual growth of +45.9% compares with a peer median of +8.6%.
PRAX Competitors Peer median
Accounts Payables for PRAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$54M ——1.5%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$25.76M +74.1%+8.6%3.1%
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$24.47M +11282.3%—2.1%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$15.8M -200.0%+45.9%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$12.66M -141.8%—1.6%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$4.34M +345.5%—21.7%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$4M +845.6%——
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$3.67M +225.9%-11.9%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$3.38M +7.9%—93.6%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$1.93M -801.1%+80.5%—
Peer median (excluding PRAX) $3.67M+150.0%+8.6%2.6%

Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.06M)(214.03M)(123.28M)(182.82M)(303.27M)
Depreciation & Amortization182K419K432K358K140K
Deferred Income Tax2.09M0000
Stock-Based Compensation22.69M28.59M24.86M41.36M33.94M
Change in Working Capital16.13M(1.78M)(13.03M)10.92M22.68M
Accounts Receivables00000
Inventory00000
Accounts Payables7.27M3.89M(8.86M)6.71M12.1M
Other Working Capital8.87M(5.67M)(4.17M)4.21M10.58M
Other Non-Cash Items1.41M1.76M(121K)(1.58M)(2.56M)
Operating Cash Flow(124.55M)(185.04M)(111.14M)(131.76M)(249.07M)
Capital Expenditures(1.05M)(444K)(50K)0(56K)
Acquisitions (Net)139.47M(97.33M)000
Purchases of Investments(164.17M)(83.02M)0(371.52M)(623.81M)
Sales of Investments24.7M180.36M39M123.03M312.72M
Other Investing Activities(139.47M)97.33M000
Investing Cash Flow(140.52M)96.89M38.95M(248.49M)(311.15M)
Debt Repayment(763K)0000
Common Stock Issued105.71M9.56M91.59M512M704.26M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.64M904K279K2.33M(2.09M)
Financing Cash Flow107.59M10.47M91.87M514.32M702.17M
Effect of Forex Changes00000
Net Change in Cash(157.49M)(77.69M)19.69M134.07M141.96M
Free Cash Flow(125.6M)(185.49M)(111.19M)(131.76M)(249.12M)

Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Intrinsic Alpha fair value

Locked

Current Price

$305.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.